药明生物续涨近4.5%破顶 君实/微创/四环/联邦制药涨4%-5%
下月7日正式「染蓝」的药明生物(02269.HK)承昨天回升近6%势,今天股价进一步突破本月6日所创上市高位193元,最高见200元,现造196.7元,续升4.4%,成交608万股(已接近昨天全日成交668万股),涉资11.94亿元。
联邦制药(03933.HK)昨天收市後公布中绩少赚31.5%至2.03亿人民币及营收年增5%,今早低开回落至8.43元获承接,掉头高见9.17元,暂受制昨天盘中所创逾两年高位9.21元,现造9.09元,续升5%。
日前公布中绩亏转赚1.5亿人民币中期共派息3.1分人民币的四环医药(00460.HK)扭两连吐股价重越10天线(0.92元),最高见0.95元,现造0.94元,回升4.4%。
微创医疗(00853.HK)扭三连跌股价重越10天线(34.9元),最高见35.15元,现造35.1元,回升4.8%。君实生物(01877.HK)也扭三连跌股价重越10天线(49.2元),报49.95元即市高位,回升4%。
昨天中午放榜中绩多赚23%及恢复派发中期息兼送红股的蓝筹石药集团(01093.HK)高见17.28元,暂受制去年11月所创52周高位18元,现造17元,续升2.2%。
相反,早前公布中绩少赚近3%的国药(01099.HK)续跌2.5%报18.8元。神威药业(02877.HK)、绿叶制药(02186.HK)及三生制药(01530.HK)回吐1.8%-2.3%,分别报5.32元/4.86元/9.1元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.